page full analyst note may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim
price data may
rate updat may
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
myriad acquisit divestitur past decad
constant state evolut
medic imag divestitur structur chang
histor constrain margin confid firm
renew strateg focu toward improv diagnost product
mix life scienc busi sustain return cost
capit long run competit posit
certainli shift better sever attract avenu
growth reach particularli emerg market believ
firm produc tangibl benefit sharehold next
crown
jewel
product portfolio firm hold lead posit
neonat prenat matern test screen bulk
babi test world-wide market character
stabl profit price power main opportun
newborn screen busi lie oversea emerg market
half chines newborn screen
kit major undergo test three four
disord compar disord firm
capit vast potenti market along
india latin america emerging-market opportun also
abound firm infecti diseas product line
environment segment grow emphasi qualiti life
segment posit benefit strong secular
demand emerging-market revenu expect
import growth contributor go forward especi
expect synergi euroimmun vanadi
shift product mix toward diagnost life scienc
help lessen exposur lower-growth industri end
market offer better growth profil remain
cautiou whether manag capital-alloc strategi
creat valu believ compani taken step shed
weak asset support attract diagnost acquisit
start billion euroimmun purchas
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
provid instrument consum servic
pharmaceut biomed chemic environment gener
industri market compani oper two segment diagnost
includ prenat screen infectious-diseas test
discoveri analyt solut compos life scienc industri
environment food applic offer product
servic rang genet screen environment analyt tool
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
narrow-moat report first-quart result
rel stabl neg impact relat
pandem certain end-market partial off-set
strong resili busi geograph mix firm
gener earn per share million
sale surpass capit iq consensu
million respect manag pull guidanc
on-going crisi
consid potenti rebound futur period
expect make materi chang fair
quarter gener adjust revenu
growth year year driven demand variou
market off-set condit china
account total compani revenu
adjust oper margin declin
basi point thank strong cost control allevi
revenu damag oper segment
discoveri analyt solut da diagnost
experienc organ revenu declin year
year da firm gener high-single-digit revenu
growth life scienc busi due solid demand
enterpris discoveri product among pharmaceut
biotech firm constrast food appli market
affect double-digit declin diagnost
steer way appli genom report double-
digit organ growth base momentum across
geographi benefit covid rt-pcr workflow
reproduct health immunodiagnost gener
mid-single-digit declin posit test demand
america europ off-set market pressur
manag provid color upcom quarter
ep estim least revenu
million flat organ
outlook rang highli depend futur market
condit across geograph front supplement
recur revenu product portfolio firm
expect pressur da segment estim
headwind declin
revenu partial off-set expect tailwind
revenu diagnost notabl
elisa boast specif sensit
howev remain uncertain particular
immunoassay fare term price demand
versu larger competitor overal encourag
diversifi product mix high accuraci
serolog test better margin enabl firm
mitig declin felt china end
comprehens review
increas fair valu estim per share
mainli result higher confid firm
abil gener consist return cost capit
long run reflect new narrow moat
rate valuat impli adjust price-to-earnings
multipl approxim time expect earn
well posit gener ep growth
approxim compound annual next five
top line expect approxim revenu
growth driven mostli
compani enhanc mix shift diagnost life
scienc emerging-market opportun
newborn screen reproduct health remain healthi
continu growth compani euroimmun
acquisit add increment benefit compani
diagnost channel predict discoveri
analyt solut segment post low-single-digit
organ growth forecast period furthermor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
experi success grow euroimmun presenc
case forecast averag revenu growth
diagnost approxim next five year
expect overal revenu growth compound
annual slight increas base-cas
oper margin rise approxim
forecast period believ adjust earn per share
grow compound annual next
five year valu time project
earn scenario
bear-cas scenario fair valu estim per
appli end life scienc analyt
solut segment gener averag revenu growth
next five year emerg market headwind
reduc diagnost revenu growth approxim
compound annual assumpt push overal
revenu growth assumpt compound
annual next five year also expect
adjust earn per share grow compound
annual scenario valu time
narrow econom moat anchor
signific intang asset custom switch cost
past five year undergon
substanti oper transit firm
primarili defin environment health industri
end market account approxim
revenu segment make
revenu expect histor low-growth
busi continu fade manag deploy
capit new growth initi attract human
health-rel end market discoveri
analyt solut segment previous tie
cyclic end market manag pivot invest
recent meizheng acquisit food safeti
add demand analyt instrument
bolster firm environment food busi
compani growth margin return invest
capit profil improv sale medic
imag busi recent oper
posit optim infrastructur boost
adjust oper margin approxim
next five year averag five-year return capit hover
near model assum compani weight
averag cost capit approxim
bull-cas scenario expect fair valu estim
rise per share assum perkinelm
aggress expand autoimmun allergi test
capabl euroimmun emerg market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
toward life scienc food liquid chromatographi
mass spectrometri busi line less
cyclic overal believ enjoy benefit
intang asset patent portfolio
technolog applic switch cost
newborn screen high capit
invest industri standard make custom
hesit switch provid
firm discoveri analyt solut segment
approxim revenu possess narrow moat
analyt instrument tool use sever
environment research applic
busi gener third sale
instrument consum softwar solut
respect compani strong tie
higher-end academ pharmaceut custom
pocket analyt instrument space domin
entrench wide-moat player like agil
although creat challeng environ
drug product valid see better
execut enterpris informat discoveri
product onesourc firm complet lab servic
offer benefit high switch cost wide
breadth servic contract length rang three
five year contract expens
larg pharmaceut compani spend approxim
million per site program total
program cost could rang million per
year rank top five manag
servic special run entir preclin
laboratori top pharmaceut firm retent
rate high sinc multi-year contract tend
incorpor cost-shar agreement custom
integr lab mainten procedur onesourc
unlik switch competit product sinc would
requir addit invest time money
preclin informat custom remain risk-avers
offer broadest rental reagent portfolio
player small molecul side use proprietari
homogen time resolv fluoresc htrf
technolog chemic discoveri beyond switch cost
see intang asset protect perkinelm
discoveri analyt instrument exampl food
applic qsight lc/ms/m technolog built
use patent compon enabl high sensit
perform maximum uptim
diagnost busi amount roughli
revenu also possess narrow moat
well-establish nich newborn screen expect
perkinelm gener strong growth reproduct
health immunodiagnost appli genom test
firm appli tandem mass spectrometri ms/m
newborn screen market measur multipl
molecul significantli reduc test time
cost allow analysi chemic level
combin rather isol technolog
capabl enabl cord blood genom test
detect rare diseas newborn intangiblesinclud
firm extens test menu intellectu properti
technolog expertis establish relationship
govern hospitalsincreas barrier entri
space razor-and-blad model
newborn screen busi make custom hesit
global market share newborn screen neonat
heel-prick kit test nearli newborn babi unit
state along approxim million babi
world-wide firm hospit client appear reluct
pull system due regulatori pressur test
consist concern compani test perform
unit state emerg market particularli
china india long-term growth outlook newborn
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
view perkinelm moat trend stabl firm
reinforc switch cost offer custom
complet laboratori servic think help
compani gener econom profit least five year
expect gener steadi recur
revenu oper segment multi-year
contract broad reagent portfolio addit
expect new technolog lower cost switch
new provid custom remain risk-avers
rel matur sticki busi busi
segment sever regulatori reproduc train
barrier hinder major disrupt risk would materi
enough realli cut return
term intang asset think differenti
featur technolog remain protect
long run direct copycat precis scientif
end market patent reput effect among
factor differenti featur continu
inform end user demand firm effort innov
improv technolog help preserv relationship
biopharmaceut compani diagnost laboratori
custom futur project well
screen continu favor firm estim
third newborn babi global screen
disord everi year leav like gain
even opportun increas test penetr
util combin busi segment
vanadi euroimmun
firm launch smart nipt vanadi
simplifi cost-effect altern dna non-invasive
prenat test provid screen result trisomi
marker syndrom smart nipt first
platform streamlin screen trisomi
remov need screen complex dna
sequenc microarray process instead screen
digit analysi cell-fre dna enabl
diagnost lab instal oper connect exist
laboratori system offer test
solut gener detect rate limit fals
posit smartnipt averag per test price
premium typic biochem assess
cost per test much less accur
remain consider cheaper dna sequenc
process add firm prenat test capabl
contain high barrier entri intang
complex data treatment laboratori futur
expect synergi vanadi euroimmun
immunodiagnost allergi test busi key
driver euroimmun hold global market
share largest player autoimmun in-vitro
diagnost produc test system laboratori diagnosi
infecti diseas allergi gene analys
product portfolio protect patent last year
enabl strengthen posit
emerg market custom use test system
solut gener strong recur
revenu approxim turnov consist
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
possess well-entrench nich
newborn screen stand benefit
grow adopt menu expans emerg
odevelop countri face grow pressur
improv air water qualiti
lead provid environment test instrument
well posit profit secular trend
oeuroimmun posit strong revenu
margin growth driver especi sinc largest
player autoimmun diagnost
odeclin birth rate overpopul china
india could slow growth diagnost
particularli newborn screen
odespit strong nich servic pre-clin
drug discoveri compani prospect da
segment somewhat limit firm
strong presenc area like drug product
oalthough unlik player like agil
could focu servic busi take market
share
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
histori consist acquisit tend keep
financi leverag elev end perkinelm
held million cash compar billion debt
net debt/ebitda around time leverag ratio
slightli target time could see
de-lever go forward assum make
anoth signific debt-fund acquisit near
futur acquisit remain top capit alloc prioriti
though excess cash flow
tend engag signific share buyback compani
pay small quarterli dividend amount
million provid recent
updat pay-out ratio
rate firm restructur bolt-on acquisit
plan mostli complet believ unlik investor
face larg risk overpay integr
futur admittedli analyt solut segment
firm exposur industri environment end market
increas vulner macroeconom downturn
currenc headwind howev believ firm
grow strength enterpris discoveri life scienc
substanti enough mitig outcom
diagnost disrupt technolog involv
emerg market particularli china india impos
risk fall birth rate china caus
skeptic growth prospect relat birth screen
believ firm divers grow product line provid
enough stabil off-set headwind though
reinforc medium uncertainti rate
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
upgrad stewardship rate standard
poor confid manag team
led prahlad singh produc sharehold return
past assign poor stewardship rate
previou manag rel pedestrian
record came valu creation sharehold
return outbound ceo robert friel compani
deploy free cash flow debt proce
acquisit produc lacklust return
posit view ceo transit singh sinc join
perkinelm singh key player expand
firm product mix particularli diagnost
former presid diagnost chief oper offic
singh far shown solid track record manag
success deploy capit value-accret way
recent year reflect upgrad
stewardship rate remain somewhat cautiou
whether record hold especi end
market like life scienc diagnost gener
view trade premium fair valu pay
small quarterli dividend made announc
increas pay-out ratio
repres date owner name posit common share held report holder issuer
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
notabl firm continu deal organiz shift
near futur includ new leadership ceo
prahlad singh integr recent meizheng group
acquisit consolid effort suppli chain
structur realign
simplif process complet though believ
firm well posit gener higher return target
take fresh look rais moat
narrow none fair valu estim feb
take fresh look upgrad
firm moat rate narrow none due
enhanc outlook diagnost discoveri
analyt solut da segment improv return
invest capit believ firm divers product
line improv posit sever end market
intang asset high switch cost along
moat upgrad increas fair valu estim
per share per share recent year
firm develop strong nich servic drug
discoveri expand diagnost product portfolio
provid us confid firm abl deliv
sustain excess return capit long run
believ gener averag annual top-
line revenu growth approxim next five
year although analyt instrument space life
scienc highli fragment believ firm
posit experi low-single-digit revenu growth
primarili due strength sale enterpris
discoveri product diagnost assum high-single-
digit revenu growth approxim forecast
period thank continu strength legaci newborn
screen busi improv product mix neonat
health immunodiagnost perkinelm like
continu capit grow demand diagnost
especi vanadi euroimmun major market
share potenti exist emerg market specif
europ china manag recent provid broad-
base guidanc revenu estim
billion adjust ep estim
revenu ep estim larg line
manag expect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
